Loading...
L

Lucira Health Inc
NASDAQ:LHDX

Watchlist Manager
Lucira Health Inc
NASDAQ:LHDX
Watchlist
Price: 0.33 USD -8.33% Market Closed
Updated: Dec 6, 2022

Intrinsic Value

LHDX's intrinsic value estimate is unreliable because it is based only on its relative value.

The intrinsic value of one LHDX stock under the Base Case scenario is 4.65 USD. Compared to the current market price of 0.33 USD, Lucira Health Inc is Undervalued by 93%.

The Intrinsic Value is calculated as the average of the two valuation methods:

LHDX Intrinsic Value
Base Case
4.65 USD
Undervaluation 93%
Intrinsic Value
Price
L
Worst Case
Base Case
Best Case

Fundamental Analysis

LHDX Profitability Score
Profitability Due Diligence

Lucira Health Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

Negative 3-Year Average ROE
Negative 3-Year Average ROIC
Negative Free Cash Flow
Negative Operating Income
24/100
Profitability
Score

Lucira Health Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

LHDX Solvency Score
Solvency Due Diligence

Lucira Health Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Low Interest Coverage
Low Altman Z-Score
Negative Net Debt
Long-Term Liabilities
50/100
Solvency
Score

Lucira Health Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Financials
Efficiency
35%
Gross Margin
-22%
Operating Margin
-23%
Net Margin
-61%
FCF Margin
-22%
ROE
-33%
ROIC
Other

LHDX Capital Structure
Lucira Health Inc

Market Capitalization 13.2M USD
Total Debt 29.2M USD
Minority Interest 0 USD
Preferred Equity 0 USD
Cash and Equivalents 75M USD
Short-Term Investments 0 USD
Enterprise Value -32.5M USD

Wall St
Price Targets

LHDX Price Targets Summary
Lucira Health Inc

Wall Street analysts forecast LHDX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LHDX is 0.77 USD with a low forecast of 0.76 USD and a high forecast of 0.79 USD.

Lowest
Price Target
0.76 USD
130% Upside
Average
Price Target
0.77 USD
132% Upside
Highest
Price Target
0.79 USD
139% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

LHDX Competitors
Lucira Health Inc

LHDX Suppliers & Customers
Lucira Health Inc

Lucira Health Inc has 3 key suppliers from 3 countries and 3 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Electrical Equipment industry.

Lucira Health Inc has 3 key customers from 2 countries and 3 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Retail industry.

Ownership

LHDX Insider Trading
Buy and sell transactions by insiders

Lucira Health Inc insiders have sold more shares than they have bought in the past 12 months.

During the last 12 months Lucira Health Inc insiders bought 141k USD , and sold 192k USD worth of shares. The last transaction was made on Dec 6, 2022 by Collins Kevin Walter (Chief Revenue Officer), who sold 4.1k USD worth of LHDX shares.

Sold
0-3
months
29.9k USD
4
3-6
months
76.5k USD
5
6-9
months
75k USD
3
9-12
months
10.2k USD
2
Bought
0-3
months
1
36.4k USD
3-6
months
1
14.9k USD
6-9
months
1
90k USD
9-12
months
0
0 USD
Cumulative Transactions Amount
Period Sold Bought Net
3 Months
29.9k USD
36.4k USD
6.5k
6 Months
106k USD
51.3k USD
-55.1k
9 Months
181k USD
141k USD
-40.1k
12 Months
192k USD
141k USD
-50.3k
Purchases
4
Sales
16
Why is insider trading important?

Shareholder Return

LHDX Price
Lucira Health Inc

1M 1M
-57%
6M 6M
-81%
1Y 1Y
-95%
3Y 3Y
-98%
5Y 5Y
-98%
Annual Price Range
0.33
52w Low
0.33
52w High
8.94
Price Metrics
Average Annual Return
N/A
Standard Deviation of Annual Returns
N/A
Max Drawdown -99%
Shares Statistics
Market Capitalization 13.2M USD
Shares Outstanding 40 106 500
Percentage of Shares Shorted 0.35%

Company Profile

Lucira Health Inc

Country

United States of America

Industry

Health Care

Market Cap

13.2M USD

Dividend Yield

0%

Description

Lucira Health, Inc. provides DNA testing services for medical, forensics, chemical, industrial, and agricultural applications. The company is headquartered in Emeryville, California and currently employs 141 full-time employees. The company went IPO on 2021-02-05. The firm is focused on the development and commercialization of transformative and infectious disease test kits. The firm has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and test kit that is powered by two AA batteries and fit in the palm of a hand. Its initial focus is within respiratory diseases, starting with COVID-19 and influenza A and B virus indications. The company has developed LUCIRA COVID-19 All-In-One Test Kit (COVID-19 test kit), is a single-use, molecular in vitro diagnostic test that has an analytical sensitivity to detect the SARS-CoV-2 virus. The test is authorized for prescription at-home use.

Contact

CALIFORNIA
Emeryville
1412 62nd Street
+8145741546.0
https://www.lucirahealth.com/

IPO

2021-02-05

Employees

141

Officers

Pres, CEO & Director
Mr. Erik T. Engelson
CTO & Director
Dr. Debkishore Mitra Ph.D.
Chief Revenue Officer
Mr. Kevin Walter Collins
Chief Quality Officer & Exec. VP of Regulatory Affairs
Mr. Ghazi Kashmolah
CFO & Treasurer
Mr. Daniel V. George
Chief Operations Officer
Mr. Tony Allen
Show More
Investor Relations
Greg Chodaczek
Chief HR Officer
Dr. Nadine Greiner Ph.D.
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one LHDX stock?

The intrinsic value of one LHDX stock under the Base Case scenario is 4.65 USD.

Is LHDX stock undervalued or overvalued?

Compared to the current market price of 0.33 USD, Lucira Health Inc is Undervalued by 93%.